Furthermore, Berger et al. compared the therapeutic effects on LPS-induce cystitis mice among β-caryophyllene (a nature diet sesquiterpenoid and an agonist of CB2), HU308 (the synthetic CB2-selective cannabinoid), and dimethyl sulfoxide (an US Food and Drug Administration approved clinical treatment), in which both nature and synthetic cannabinoids significantly reduced the number of adhering leukocytes in submucosal bladder venules and improved bladder capillary perfusion in intravital microscopy [47]. The gene discussed is CNR2; the disease is cystitis.